Pfizer Lifts 2025 Forecast After Strong Q2

Pfizer reported second-quarter 2025 revenues of $14.7 billion and adjusted earnings per share of $0.78, surpassing analyst estimates. The company raised its full-year 2025 adjusted profit forecast to $2.90–$3.10 per share, citing strong sales of Vyndaqel, Eliquis, and Covid-19 products, as well as favorable foreign exchange impacts and ongoing cost reductions. Cost-saving initiatives are projected to achieve $4.5 billion in net savings by 2025 and $7.2 billion by 2027. Despite resilient sales, Pfizer faces challenges from declining Covid-19 demand, patent expirations, and new regulatory risks including potential US drug pricing reforms and proposed pharmaceutical tariffs. CEO Albert Bourla attributed the improved outlook to effective business strategy and R&D investments. The company remains focused on growth in oncology and maintaining operational efficiency.